M2PP: a novel computational model for predicting drug-targeted pathogenic proteins

Background Detecting pathogenic proteins is the origin way to understand the mechanism and resist the invasion of diseases, making pathogenic protein prediction develop into an urgent problem to be solved. Prediction for genome-wide proteins may be not necessarily conducive to rapidly cure diseases as developing new drugs specifically for the predicted pathogenic protein always need major expenditures on time and cost. In order to facilitate disease treatment, computational method to predict pathogenic proteins which are targeted by existing drugs should be exploited. Results In this study, we proposed a novel computational model to predict drug-targeted pathogenic proteins, named as M2PP. Three types of features were presented on our constructed heterogeneous network (including target proteins, diseases and drugs), which were based on the neighborhood similarity information, drug-inferred information and path information. Then, a random forest regression model was trained to score unconfirmed target-disease pairs. Five-fold cross-validation experiment was implemented to evaluate model’s prediction performance, where M2PP achieved advantageous results compared with other state-of-the-art methods. In addition, M2PP accurately predicted high ranked pathogenic proteins for common diseases with public biomedical literature as supporting evidence, indicating its excellent ability. Conclusions M2PP is an effective and accurate model to predict drug-targeted pathogenic proteins, which could provide convenience for the future biological researches.

Network pharmacology study of Citrus reticulata and Pinellia ternata in the treatment of non-small cell lung cancer

It has been recognized that Citrus reticulata and Pinellia ternata have a good therapeutic effect on NSCLC. However, the potential mechanism of C. reticulata and P. ternata in the treatment of NSCLC based on network pharmacology analysis is not clear. The “Drug-Component-Target-Disease” network was constructed by Cytoscape, and the protein interaction (PPI) network was constructed by STRING. Our study indicated that 18 active ingredients of C. reticulata and P. Ternata were screened from the TCMSP database, and 56 target genes of C. reticulata and P. Ternata for the treatment of NSCLC were identified, and we constructed the “Drug-Component-Target-Disease” network. In this study, we screened 56 PPI core genes to establish a PPI network. We concluded that the network pharmacology mechanism of the effect of C. reticulata and P. Ternata on NSCLC may be closely related to the protein expressed by TP53, ESR1, FOS, NCOA3 and MAPK8, and these may play the therapeutic roles by regulating the IL-17 signaling pathway, antigen processing and presentation, microRNAs in cancer and endocrine resistance.

Exploring the Mechanism of Panax notoginseng Saponins against Alzheimer’s Disease by Network Pharmacology and Experimental Validation

Background. Panax notoginseng saponins (PNS) have been used for neurodegenerative disorders such as cerebral ischemia and Alzheimer’s disease (AD). Although increasing evidences show the neuron protective effects of PNS, the vital compounds and their functional targets remain elusive. To explore the potential functional ingredients of PNS for the AD treatment and their molecular mechanisms, an in vitro neuron injured model induced by Aβ was investigated, and the potential mechanism was predicted by network pharmacology approach and validated by molecular biology methods. Methods. Network pharmacology approach was used to reveal the relationship between ingredient-target disease and function-pathway of PNS on the treatment of AD. The active ingredients of PNS were collected from TCMSP, PubChem database, and literature mining in PubMed database. DrugBank and GeneCards database were used to predict potential targets for AD. The STRING database was performed to reveal enrichment of these target proteins, protein-protein interactions, and related pathways. Networks were visualized by utilizing Cytoscape software. The enrichment analysis was performed by the DAVID database. Finally, neuroprotective effect and predictive mechanism of PNS were investigated in an in vitro AD model established by Aβ25–35-treated PC12 cells. Results. An ingredient-target disease and function-pathway network demonstrated that 38 active ingredients were derived from PNS modulated 364 common targets shared by PNS and AD. GO and KEGG analysis, further clustering analysis, showed that mTOR signaling targets were associated with the neuroprotective effects of PNS. In Aβ-treated PC12 cells, PNS treatment improved neuroprotective effect, including mTOR inhibition and autophagy activation. Conclusions. Collectively, the protective effects of PNS on AD-neuron injury are related to the inhibition of mTOR and autophagy activation.

Exploring the Potential Mechanism of Chuanxiong Rhizoma Treatment for Migraine Based on Systems Pharmacology

Migraine is a disease whose aetiology and mechanism are not yet clear. Chuanxiong Rhizoma (CR) is employed in traditional Chinese medicine (TCM) to treat various disorders. CR is effective for migraine, but its active compounds, drug targets, and exact molecular mechanism remain unclear. In this study, we used the method of systems pharmacology to address the above issues. We first established the drug-compound-target-disease (D-C-T-D) network and protein-protein interaction (PPI) network related to the treatment of migraine with CR and then established gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The results suggest that the treatment process may be related to the regulation of inflammation and neural activity. The docking results also revealed that PTGS2 and TRPV1 could directly bind to the active compounds that could regulate them. In addition, we found that CR affected 11 targets that were more highly expressed in the liver or heart but were the lowest in the whole brain. It also expounds the description of CR channel tropism in TCM theory from these angles. These findings not only indicate that CR can be developed as a potential effective drug for the treatment of migraine but also demonstrate the application of systems pharmacology in the discovery of herbal-based disease therapies.

Synthesis of N-Glycans and Azasugars to Target Disease

<p>In this thesis two aspects of carbohydrate research will be discussed. First, the total synthesis of N-glycans found on allergens that are known to stimulate an allergic immune response and second, the synthesis of iminosugars in an attempt to extend the scope of the PGF-methodology. Asthma affects 235 million people worldwide, with New Zealand ranking among the highest in the world. Although there is a good understanding of how allergens trigger the immune system on a “macroscopic” level, how an allergen’s molecular structure causes such an allergic response remains unknown. Upon close review of carbohydrates present on the allergens that are known to give an allergic T helper (Th 2) immune response, a common structure has been identified. The structure consists of a complex type N-glycan made up of a pentasaccharide core (Man3(GlcNHAc)2), with additional 1,3-linked α-L-fucose and 1,2-linked D-xylose cappings. As part of a structure relationship study this heptasaccharide and structural derivatives thereof have been synthesised. The synthesis of these N-glycans will allow a more detailed study of the role of these defined structures in triggering an allergic immune response. The second part of this thesis focuses on the protecting group free (PGF) synthesis of iminosugars, which are potent glycosidase inhibitors and are currently used in the treatment of a variety of diseases. Synthetic strategies for the synthesis of iminosugars involve the use of protecting groups, which are necessary to block potential competing reactive centres within a molecule during the multistep synthesis. The disadvantage, however, is that the installation of protecting groups introduces additional steps to the total synthesis, which inevitably leads to lower yields and the generation of waste. Within our group, PGF methodologies have been developed which allow for the synthesis of a variety of iminosugars. The work presented in this thesis extends the scope of this methodology for the synthesis of an important class of iminosugars, the 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidines. For the purpose of introducing an additional hydroxymethyl group, a ketose starting material was required, and therefore an efficient Vasella/reductive amination reaction using ketoses was developed. Additionally, iodocyclisation and carbamate annulation of the intermediate alkenylamines provided successful entry to the 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidines, exemplified by the efficient 6-step synthesis of 2,5-dideoxy-2,5-imino-L-iditol and 2,5-dideoxy-2,5-imino-D-mannitol (DMDP).</p>

Synthesis of N-Glycans and Azasugars to Target Disease

<p>In this thesis two aspects of carbohydrate research will be discussed. First, the total synthesis of N-glycans found on allergens that are known to stimulate an allergic immune response and second, the synthesis of iminosugars in an attempt to extend the scope of the PGF-methodology. Asthma affects 235 million people worldwide, with New Zealand ranking among the highest in the world. Although there is a good understanding of how allergens trigger the immune system on a “macroscopic” level, how an allergen’s molecular structure causes such an allergic response remains unknown. Upon close review of carbohydrates present on the allergens that are known to give an allergic T helper (Th 2) immune response, a common structure has been identified. The structure consists of a complex type N-glycan made up of a pentasaccharide core (Man3(GlcNHAc)2), with additional 1,3-linked α-L-fucose and 1,2-linked D-xylose cappings. As part of a structure relationship study this heptasaccharide and structural derivatives thereof have been synthesised. The synthesis of these N-glycans will allow a more detailed study of the role of these defined structures in triggering an allergic immune response. The second part of this thesis focuses on the protecting group free (PGF) synthesis of iminosugars, which are potent glycosidase inhibitors and are currently used in the treatment of a variety of diseases. Synthetic strategies for the synthesis of iminosugars involve the use of protecting groups, which are necessary to block potential competing reactive centres within a molecule during the multistep synthesis. The disadvantage, however, is that the installation of protecting groups introduces additional steps to the total synthesis, which inevitably leads to lower yields and the generation of waste. Within our group, PGF methodologies have been developed which allow for the synthesis of a variety of iminosugars. The work presented in this thesis extends the scope of this methodology for the synthesis of an important class of iminosugars, the 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidines. For the purpose of introducing an additional hydroxymethyl group, a ketose starting material was required, and therefore an efficient Vasella/reductive amination reaction using ketoses was developed. Additionally, iodocyclisation and carbamate annulation of the intermediate alkenylamines provided successful entry to the 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidines, exemplified by the efficient 6-step synthesis of 2,5-dideoxy-2,5-imino-L-iditol and 2,5-dideoxy-2,5-imino-D-mannitol (DMDP).</p>

A Network Pharmacology Study to Explore Mechanism of the Drug Pair of Astragalus-Saposhnikoviae Radix in the Treatment of Allergic Rhinitis

Allergic rhinitis (AR) has now become one of the major diseases affecting people’s lives, and Traditional Chinese medicine (TCM) always has good efficacy in clinical treatment. In the present study, we analyzed the most frequently used drug pair of Astragalus-Saposhnikoviae Radix (SR) in prescriptions for the treatment of allergic rhinitis by network pharmacology to reveal the modern pharmacological mechanisms of drug prevention and treatment of the disease. Firstly, the 38 active ingredients with good ADME properties from the Astragalus-SR drug pair were collected from the database, and the collated drug targets of Astragalus and SR and the targets of allergic rhinitis were mapped against each other by the network visualization software Cytoscape, followed by the establishment of a “drug active ingredient-target-disease” network diagram and the construction of a high-confidence protein-protein interaction network. Then, the common targets obtained from the disease and drug active ingredients were imported by R language for GO enrichment analysis and KEGG pathway enrichment analysis. The KEGG pathways associated with the targets of Astragalus and SR for the treatment of allergic rhinitis obtained from R enrichment analysis were imported into Cytoscape, and the CytoNCA plug-in was loaded to construct a “target-pathway” network map, and the core target wogonin (FN1) was screened. These evidences suggest that the drug pair of Astragalus-SR works in a multi-component, multi-target and integrated modulation manner for the treatment of allergic rhinitis, which provides an important basis for the treatment of allergic rhinitis.

Vaccine Clinical Development

Vaccine Clinical Development is an integrated part of the overall process of vaccine development, which involves clinical trials in which study participants are usually prospectively and randomly allocated to receive the vaccine candidate or a control vaccine. Participants are then actively monitored to generate information on safety, and often immune responses and/or cases of the target disease. Clinical development starts with small phase 1 studies in tens or hundreds of volunteers. In phase 2, volunteers in the target population are studied for safety and evidence of a desired effect, often an immune response. In phase 3, pivotal studies will generally examine prevention of the target disease with at least 3000 participants receiving the vaccine candidate. The key outputs are reports for regulatory agencies, policy makers and health care workers to support marketing approval and appropriate ways to use the vaccine. Clinical trial designs and results are made public through registries and peer-reviewed publications.

Why Should We Implement a System of Endoscopic Retrograde Cholangiopancreatography Certification?

The endoscopic retrograde cholangiopancreatography (ERCP) procedure requires concentration while wearing a heavy radiation protective suit and taking the risk of radiation exposure and complications. In order to successfully perform an ERCP procedure, it is necessary to understand the target disease, as well as appropriate education and training, and a certain amount of experience in the procedure. The Korean Pancreatobiliary Association organized a promotion committee to implement the “ERCP Certification” system to maintain education and quality control of ERCP procedures. A blueprint was prepared.

Identification of Key Pathways and Targets of Kai Xin San in The Treatment of Alzheimer's Disease Based On a Network Pharmacology Approach and Experimental Validation

Background: Alzheimer's disease (AD) is the commonest neurodegenerative disease characterized with a progressive loss of cognitive functions and memory decline. Kai Xin San (KXS), a traditional Chinese herbal classic prescription, has been used to ameliorate cognitive dysfunction for thousands of years. However, its specific pharmacological molecular mechanisms have not been fully clarified.Methods: The ingredients of KXS and their corresponding targets were firstly screened from ETCM database. AD-related target proteins were obtained from Malacards database and DisGeNet database. Venn diagram was used to intersect the common targets between KXS and AD. Then, key ingredients and key targets were identified from compound-target-disease network and protein-protein interaction (PPI) network analysis respectively. Moreover, the binding affinity between the key ingredients and targets were verified by molecular docking. KEGG enrichment analysis further predicted the potential key signaling pathway involved in the treatment of KXS on AD, and the predicted signaling pathway was validated via experimental approach.Results: A total of 38 ingredients and 469 corresponding targets were screened, and 264 target proteins associated with AD were obtained. Compound-target-disease network and PPI identified the key active ingredients and targets, which correlate with the treatment of KXS on AD. Molecular docking revealed a good binding affinity between key ingredients and targets. KEGG pathway analysis suggested the potential effect of KXS in treatment of AD via Aβ-GSK3β-Tau pathway. Aβ1-42-injected induced a decline in spatial learning and memory and upregulated the expression of GSK3β and CDK5 along with the downregulated PP1 and PP2 expression. However, KXS significantly improve the cognitive deficits induced by Aβ1-42, decrease the GSK3β and CDK5 levels and increase the expression of PP1 and PP2.Conclusions: Our research elucidated that KXS exerted neuroprotective effects through regulating the Aβ-GSK3β-Tau signaling pathway, which provided a novel insight into the therapeutic mechanism of KXS in treatment of AD.